Find any stock by ticker or company name
NYQ – Real Time Price. Currency in USD
15.91
+0.26 (1.66%)
At close: Jun 26, 2026, 4:00 PM EDT
15.91
0.00 (0.00%)
After-hours: Jun 26, 2026, 6:19 PM EDT
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
| Name | Position |
|---|---|
| Dr. Seigo Izumo | Chair of Management Board |
| Michael Fox | Chief Operating Officer |
| Mr. Gabriele Ricci | Chief Data & Technology Officer |
| Mr. Haruhiko Hirate | Member of Management Board |
| Mr. Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department |
| Mr. Salvatore Alesci M.D., Ph.D. | Member of Management Board and Head of R&D Global Science & Biomedical Policy |
| Norimasa Takeda | Chief Accounting Officer & Corporate Controller |
| Date | Type | Document |
|---|---|---|
| 2026-06-26 | 6-K | form6k_062626.htm |
| 2026-06-24 | 6-K | form6k-1_062426.htm |
| 2026-06-17 | IRANNOTICE | iran_notice.htm |
| 2026-06-09 | 6-K | form6k_060926.htm |
| 2026-06-05 | 6-K | form6k_060526.htm |
| 2026-06-01 | 6-K | form6k_060126.htm |
| 2026-05-26 | 6-K | form6k_052626x4.htm |
| 2026-05-22 | SD | formsd_052226.htm |
| 2026-05-19 | 6-K | form6k_051926.htm |
| 2026-05-13 | 6-K | form6k-2_051326.htm |